Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will participate in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” during the BMO Biopharma Spotlight Series on March 28, 2023, at 9:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will participate in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” during the BMO Biopharma Spotlight Series on March 28, 2023, at 9:00 AM ET. The live event is exclusive to BMO clients, with a replay available later on the Company’s website. Solid Biosciences is focused on developing genetic medicines for neuromuscular and cardiac diseases, with key programs including SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy. The Company aims to improve patients' lives through scientific and technological advancement.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was -1.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the BMO Biopharma Spotlight Series: Genetic Medicine Delivery in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” on Tuesday, March 28, 2023 at 9:00 AM ET.
The event will be made available live only to clients of BMO. Following the event, a replay of the panel discussion will be available on the Events page of the Investors section of the Company website.
Institutional investors interested in meeting with management during the conference may reach out to their BMO representative.
About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Solid Biosciences Media Contact:
Tim Palmer
Associate Director, Corporate Communications
607-760-4223
Tim@solidbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.